BioCryst Pharmaceuticals, Inc.
BCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $450,712 | $331,412 | $270,827 | $157,170 |
| % Growth | 36% | 22.4% | 72.3% | – |
| Cost of Goods Sold | $12,485 | $4,661 | $6,594 | $7,264 |
| Gross Profit | $438,227 | $326,751 | $264,233 | $149,906 |
| % Margin | 97.2% | 98.6% | 97.6% | 95.4% |
| R&D Expenses | $174,638 | $216,566 | $253,297 | $208,808 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $266,132 | $213,894 | $159,371 | $118,818 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $440,770 | $430,460 | $412,668 | $327,626 |
| Operating Income | -$2,543 | -$103,709 | -$148,435 | -$177,720 |
| % Margin | -0.6% | -31.3% | -54.8% | -113.1% |
| Other Income/Exp. Net | -$84,411 | -$122,520 | -$95,948 | -$4,089 |
| Pre-Tax Income | -$86,954 | -$226,229 | -$244,383 | -$181,809 |
| Tax Expense | $1,927 | $310 | $2,733 | $2,253 |
| Net Income | -$88,881 | -$226,539 | -$247,116 | -$184,062 |
| % Margin | -19.7% | -68.4% | -91.2% | -117.1% |
| EPS | -0.43 | -1.18 | -1.33 | -1.03 |
| % Growth | 63.6% | 11.3% | -29.1% | – |
| EPS Diluted | -0.43 | -1.18 | -1.33 | -1.03 |
| Weighted Avg Shares Out | 206,696 | 192,198 | 185,908 | 179,117 |
| Weighted Avg Shares Out Dil | 206,696 | 192,198 | 185,908 | 179,117 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14,746 | $15,777 | $5,127 | $62 |
| Interest Expense | $98,516 | $108,239 | $99,092 | $59,294 |
| Depreciation & Amortization | $1,246 | $1,655 | $1,437 | $777 |
| EBITDA | $12,808 | -$116,335 | -$143,854 | -$121,738 |
| % Margin | 2.8% | -35.1% | -53.1% | -77.5% |